Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJan 18, 2026
DataAggregated Company Financials
Companies21
  • 7D1.7%
  • 3M10.1%
  • 1Y-27.8%
  • YTD14.7%

In the last week, the Healthcare industry is up 1.7%, with Novo Nordisk up 2.0%. However, the industry is down 28% over the past year. Earnings are forecast to grow by 5.7% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 18 Jan 2026DKK 2.2tDKK 454.1bDKK 137.0b18.6x16.4x4.9x
Tue, 16 Dec 2025DKK 1.9tDKK 453.7bDKK 136.9b16.9x13.9x4.2x
Thu, 13 Nov 2025DKK 1.9tDKK 453.4bDKK 136.0b18.2x14.2x4.3x
Sat, 11 Oct 2025DKK 2.2tDKK 447.6bDKK 141.8b18.2x15.4x4.9x
Mon, 08 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.5x4.6x
Wed, 06 Aug 2025DKK 1.8tDKK 423.5bDKK 124.6b29.5x14.5x4.3x
Fri, 04 Jul 2025DKK 2.4tDKK 423.0bDKK 124.4b30.5x19.2x5.6x
Sun, 01 Jun 2025DKK 2.5tDKK 423.9bDKK 124.7b30.4x19.9x5.8x
Tue, 29 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b22x19x5.6x
Thu, 27 Mar 2025DKK 2.7tDKK 409.6bDKK 121.3b23.5x22.3x6.6x
Sat, 22 Feb 2025DKK 3.3tDKK 410.0bDKK 121.4b28.1x27.6x8.2x
Mon, 20 Jan 2025DKK 3.1tDKK 387.5bDKK 111.3b28.5x27.9x8x
Wed, 18 Dec 2024DKK 3.9tDKK 387.4bDKK 111.3b30.1x35.5x10.2x
Fri, 15 Nov 2024DKK 3.9tDKK 387.1bDKK 110.8b31.9x35.3x10.1x
Sun, 13 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Tue, 10 Sep 2024DKK 4.5tDKK 372.0bDKK 107.2b35x42.5x12.2x
Thu, 08 Aug 2024DKK 4.3tDKK 355.3bDKK 106.3b36.2x40.2x12x
Sat, 06 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.3x46.2x13.8x
Mon, 03 Jun 2024DKK 4.7tDKK 355.3bDKK 106.2b36.8x44.1x13.2x
Wed, 01 May 2024DKK 4.6tDKK 341.4bDKK 99.6b33.7x46x13.4x
Fri, 29 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Sun, 25 Feb 2024DKK 4.4tDKK 340.1bDKK 98.9b38.2x44.2x12.9x
Tue, 23 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b35.2x41.8x11.7x
Thu, 21 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b32.6x40.1x11.3x
Sat, 18 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33.7x40x11.2x
Mon, 16 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b30.7x45x12.1x
Wed, 13 Sep 2023DKK 3.2tDKK 305.5bDKK 82.2b35.3x39x10.5x
Fri, 11 Aug 2023DKK 3.3tDKK 288.2bDKK 74.9b42.1x44.4x11.5x
Sun, 09 Jul 2023DKK 2.9tDKK 287.0bDKK 75.5b39.4x38.9x10.2x
Tue, 06 Jun 2023DKK 3.0tDKK 287.2bDKK 75.5b39.7x39.6x10.4x
Thu, 04 May 2023DKK 3.1tDKK 272.6bDKK 68.9b41.6x45.1x11.4x
Sat, 01 Apr 2023DKK 3.0tDKK 291.1bDKK 69.0b38.5x43.6x10.3x
Mon, 27 Feb 2023DKK 2.8tDKK 292.1bDKK 68.8b38.1x40.6x9.6x
Wed, 25 Jan 2023DKK 2.7tDKK 275.9bDKK 66.3b38.3x40.9x9.8x
Price to Earnings Ratio

40.9x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 66.3bTotal Revenue: DKK 275.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 16.4x which is lower than its 3-year average PE of 33.7x.
  • The 3-year average PS ratio of 9.5x is higher than the industry's current PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.78%
Healthcare1.72%
Medical Equipment2.36%
Pharma1.87%
Biotech0.11%
Life Sciences-3.14%
Healthtech-3.73%
Healthcare Services-6.02%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 248x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 103% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 388.902.0%
+DKK 33.1b		-32.4%PE16.7x
COLO B ColoplastDKK 577.402.0%
+DKK 2.6b		-28.5%PE35.8x
DEMANT DemantDKK 233.003.9%
+DKK 1.9b		-19.7%PE18.6x
HLUN B H. LundbeckDKK 46.523.7%
+DKK 1.7b		15.5%PE12.1x
AMBU B AmbuDKK 91.252.8%
+DKK 660.0m		-34.2%PE39.9x

Latest News

NOVO B
DKK 388.90
Novo Nordisk
7D
2.0%
1Y
-32.4%

Novo Nordisk A/S' (CPH:NOVO B) 26% Share Price Surge Not Quite Adding Up

Jan 17
Novo Nordisk A/S' (CPH:NOVO B) 26% Share Price Surge Not Quite Adding Up
GMAB
DKK 2,185.00
Genmab
7D
0.1%
1Y
44.7%
NNIT
DKK 48.20
NNIT
7D
-3.6%
1Y
-48.2%
HLUN B
DKK 46.52
H. Lundbeck
7D
3.7%
1Y
15.5%

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
ALK B
DKK 224.00
ALK-Abelló
7D
-2.6%
1Y
48.6%

ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects

Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).
AMBU B
DKK 91.25
Ambu
7D
2.8%
1Y
-34.2%

AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside

Analysts now set Ambu's price target at €139, down from €147, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that adjust their valuation framework. What's in the News Ambu A/S is set to be removed from the OMX Copenhagen 20 Index, which may affect how some index and benchmark focused investors view or hold the stock (Key Developments).
EMBLA
DKK 32.60
Embla Medical hf
7D
-0.6%
1Y
-7.4%

EMBLA: Ukraine Program And Buybacks Will Support Future Margin Stability

Analysts have kept their fair value estimate for Embla Medical hf unchanged at €34.00. They have updated assumptions around discount rate, revenue growth, profit margins and future P/E to reflect a slightly different balance of risk and profitability in their models.
ZEAL
DKK 419.50
Zealand Pharma
7D
-0.1%
1Y
-41.2%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
COLO B
DKK 577.40
Coloplast
7D
2.0%
1Y
-28.5%

COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside

Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.
GUBRA
DKK 474.00
Gubra
7D
-7.9%
1Y
-25.5%
DEMANT
DKK 233.00
Demant
7D
3.9%
1Y
-19.7%

DEMANT: Future Earnings Resilience Will Rely On Stable Market Position

Analysts have trimmed their price target on Demant slightly from DKK 271.65 to DKK 268. This reflects modestly softer assumptions for revenue growth and future P/E, partly offset by a marginally higher expected profit margin and recent views that organic revenue share gains may be limited for now.
BAVA
DKK 199.15
Bavarian Nordic
7D
0.3%
1Y
1.4%

BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside

Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.
SMSMED
DKK 3.75
Scandinavian Medical Solutions
7D
-6.0%
1Y
-32.8%
BIOPOR
DKK 1.06
BioPorto
7D
-1.5%
1Y
-28.5%
STENO
DKK 1.49
Stenocare
7D
-11.1%
1Y
85.6%
PEG
DKK 0.11
Pharma Equity Group
7D
10.5%
1Y
-34.0%